ABSTRACT THAB0108LB Superiority of paclitaxel compared to either bleomycin/vincristine or etoposide as initial chemotherapy for advanced AIDS-KS in resource-limited.

Slides:



Advertisements
Similar presentations
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Advertisements

Oncologic Drugs Advisory Committee
Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257.
Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
1 November 2005 ODAC: DOXIL ®, AIDS-related KS ODAC Discussion on Accelerated Approval 8 November 2005 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.
KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
Genotype-directed dosing for Efavirenz
Switch to PI/r monotherapy
Treatment-Naïve Adults
CCO Independent Conference Coverage
CCO Independent Conference Highlights
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma CCO Independent Conference Highlights*
CCO Independent Conference Highlights
Alessandra Gennari, MD PhD
As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited.
Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
VESTED Quiz Game
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
Attal M et al. Proc ASH 2010;Abstract 310.
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
VESTED Quiz Game
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
Vahdat L et al. Proc SABCS 2012;Abstract P
New Findings in Hematology: Independent Conference Coverage
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Mateos MV et al. Proc ASH 2013;Abstract 403.
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
Goede V et al. Proc ASH 2014;Abstract 3327.
Intervista a Lucio Crinò
Fowler NH et al. Proc ASCO 2010;Abstract 8036.
Barrios C et al. SABCS 2009;Abstract 46.
Clinical Track Summary
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Domenica 03 giugno Highlight a cura di Filippo de Marinis
Gordon LI et al. Proc ASH 2010;Abstract 415.
Comparison of NNRTI vs PI/r
Switch to ATV/r monotherapy
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Coiffier B et al. Proc ASH 2011;Abstract 265.
Presentation transcript:

ABSTRACT THAB0108LB Superiority of paclitaxel compared to either bleomycin/vincristine or etoposide as initial chemotherapy for advanced AIDS-KS in resource-limited settings: A multinational randomized trial of the ACTG and the AIDS Malignancy Consortium July 26, 2018

A5263/AMC-066 Chairs Margaret Borok (University of Zimbabwe) A Randomized Comparison of Three Chemotherapy Regimens as an Adjunct to Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings A5263/AMC-066 Chairs Margaret Borok (University of Zimbabwe) Susan Krown (AIDS Malignancy Consortium)

Background & Rationale AIDS/KS contributes to morbidity and mortality in resource-limited settings (RLS) where HIV and KSHV co-infection is common AIDS/KS presents from mild to advanced disease ART is essential treatment for all stages of AIDS/KS Systemic chemotherapy indicated for advanced-stage (T1) AIDS/KS No evidence-based SOC in RLS to guide optimal use of chemotherapy with ART A well-designed clinical study is needed

Factors influencing selection of chemotherapy include: Anti-tumor activity (response rate, duration) Effects on QoL (relief of KS-associated signs and symptoms, drug-related toxicities, adherence) Potential drug-drug interactions Ease of administration (oral vs intravenous) Cost (may vary over time and in different settings)

Potential Benefits and Risks of Different Regimens Drug Regimen Benefits Risks Etoposide (ET) Oral administration Activity against KS in pre-ART era Neutropenia Secondary leukemia/ myelodysplasia Bleomycin + Vincristine (BV) Standard regimen in RLS - familiarity with use Minimal/mild hematologic toxicity Inexpensive and widely available Pulmonary toxicity (B) Cutaneous toxicity (B) Peripheral neuropathy (V) Vesicant (V) Infusion reactions (B) Paclitaxel (PTX) U.S. FDA-approved for this indication Standard regimen in high-resource settings (usually 2nd line) Peripheral neuropathy Premedication to prevent hypersensitivity reactions Special filters for administration All available as generics. All are included in 2017 WHO Model List of Essential Medicines. All have potential DDIs with ART

Study Overview Prospective, randomized, active-controlled, three-arm clinical trial Compare three regimens of chemotherapy + ART for treatment of advanced AIDS-KS in resource-limited setting Oral etoposide (ET) + ART Bleomycin and Vincristine (BV) + ART Paclitaxel (PTX) + ART Noninferiority: demonstrating clinical efficacy rate in the investigational arms is within 15% of the efficacy rate in the PTX+ART arm. Original sample size of 706 gave 88% power to demonstrate NI assuming true PFS rate in each arm is 65%.

Eligibility Adults (≥18) with confirmed HIV infection Limited(28 →42 days) or no prior ART Biopsy diagnostic of KS reviewed by study-approved pathologist No prior KS treatment Advanced KS stage (T1), i.e. any of the following: symptomatic tumor-associated edema tumor ulceration extensive oral KS gastrointestinal KS KS in any other non-nodal visceral organ (e.g., lung) Measurable cutaneous lesions Adequate hematologic, hepatic, renal, pulmonary function; KPS ≥60

Statistical Considerations Primary Endpoint Progression Free Survival (PFS) through week 48 Defined as: lack of KS progression, death, entry to another step, or loss to follow-up Primary Analysis Construct 95% CI for difference in PFS rates between treatment arms Examine if CI excludes 15% NI margin Interim Analyses Treatment arms compared at all DSMB reviews CI size based on available statistical information (e.g., 33% statistical information = 99.98% CI) Predicted Interval Plots used to assess power at the end of the study given current trends

Study Timeline DSMB #3 DSMB #6 First Accrual Protocol v1 ET arm closed Based on analysis of 257 participants (67% of planned total) randomized to the two remaining study arms, DSMB recommended stopping the study Included analyses predicting final results of the study if enrollment and follow-up continued as planned for different assumptions about future data, and further supported by Step 3 response Study Timeline DSMB #3 ET arm closed DSMB #6 Accrual closed First Accrual Protocol v1 Protocol v2 Oct-2010 Aug-2012 Mar-2016 Oct-2013 Mar-2018 Based on analysis of the first 118 participants, DSMB recommended closure of ET arm based on primary endpoint analysis Study revised as a 2-arm comparison with sample size of 386 with 80% power to demonstrate NI assuming true PFS rate in each arm is 65%

Baseline Characteristics   RANDOMIZED TREATMENT ARM ALL PARTICIPANTS N=316 ET + ART N=59 BV + ART N=125 PTX + ART N=132 Women 22% 23% Age 35 (31, 42) (30, 42) (31, 40) (31, 41) KPS ≥ 90 56% 60% 54% 57% Visceral KS 35% 27% 24% KS-associated Edema 95% 94% 89% 92% Oral KS 68% 63% CD4 count (cells/mm3) 194 (99, 318) 230 (134, 369) 232 (125, 348) 228 (120, 362) HIV VL < 400 c/mL 7% 21% 26% ART Regimen: EFV/FTC/TDF 96%

Progression-free survival by treatment group (numbers of participants as of the time of the last DSMB review prior to arm closure) -20% PFS difference CI for difference excludes zero difference Prediction showed low chance of showing NI and current result unlikely to change Ad-hoc summary showed better response with PTX as second-line therapy than BV 63% 43% PTX + ART BV + ART ET + ART -39.4% PFS difference More than -25% team threshold Consistent trend over time that ET worse than PTX CI for difference almost excludes zero difference Prediction showed low chance of showing NI 19%

Targeted Toxicities (Grade 3 or higher) on Step 1 Event Type Randomized Treatment Arm ET + ART N=59 BV + ART N=125 PTX + ART N=132 Neutropenia 12% 11% Anemia 2% 9% 5% Thrombocytopenia 1% Dyspnea Sensory Neuropathy Infections 18% 16% Death by week 48

CD4 Count Changes – HIV-RNA Suppression Median (IQR) (VL <50 copies/ml) BV + ART ET + ART PTX + ART

Conclusions PTX + ART established as a SOC for initial treatment of advanced AIDS-KS in RLS Increased PFS compared to oral ET+ART or BV+ART. Similar adverse event profiles of the 3 regimens. Similar profiles for CD4 count recovery and HIV-RNA suppression. Additional secondary analyses to include components of the primary endpoint, QoL, viral and cellular gene expression, cellular and humoral markers of immune function and activation, PK interaction substudy. Possible cost-effectiveness analysis to further inform drug policy. Need to improve cancer therapeutic infrastructure and accessibility of essential chemotherapeutic agents in RLS.

Acknowledgments Statisticians (SDAC) Carlee Moser Roy Matining Scott Evans Protocol Vice-Chairs Tom Campbell Patrick MacPhail Bill Wachsman FSTRF Data Manager Stephanie Caruso Protocol Specialists Lara Hosey Jennifer Rothenberg Sean McCarthy DAIDS Medical Officer Catherine Godfrey Director, AIDS Cancer Clinical Program, NCI/OHAM Mostafa Nokta Lead Site Investigators Agnes Moses (Lilongwe) Wadzanai Samaneka (Harare) Mulinda Nyirenda (Blantyre) Naftali Busakhala (Eldoret) Henriette Burger (Cape Town) Noluthando Mwelase (Johannesburg) Brenda Hoagland (Rio) Josphat Kosgei (Kericho) Jackson Orem (Kampala) Vincent Otieno (Kisumu) Rosie Mngqibisa (Durban) Pharmaceutical Support Bristol-Myers Squibb Gilead Merck Grant support UM1CA121947 UM1AI068636 UM1AI068634 Special Thanks to: Tim Wilkin; GCAB; AMC CAB; CRS Leaders, The Participants!